Otterbein University

Digital Commons @ Otterbein
Nursing Student Class Projects (Formerly MSN)

Student Research & Creative Work

7-2016

Japanese Octopus Traps & Broken Hearts: Takotsubo
Cardiomyopathy
Chase A. Smith
Otterbein University, chase.smith@otterbein.edu

Follow this and additional works at: https://digitalcommons.otterbein.edu/stu_msn
Part of the Nursing Commons

Recommended Citation
Smith, Chase A., "Japanese Octopus Traps & Broken Hearts: Takotsubo Cardiomyopathy" (2016). Nursing
Student Class Projects (Formerly MSN). 161.
https://digitalcommons.otterbein.edu/stu_msn/161

This Project is brought to you for free and open access by the Student Research & Creative Work at Digital
Commons @ Otterbein. It has been accepted for inclusion in Nursing Student Class Projects (Formerly MSN) by an
authorized administrator of Digital Commons @ Otterbein. For more information, please contact
digitalcommons07@otterbein.edu.

Japanese Octopus Traps & Broken Hearts: Takotsubo Cardiomyopathy
Chase Smith BSN, RN, CCRN
Otterbein University, Westerville, Ohio

Significance of Pathophysiology

Introduction
-Takotsubo cardiomyopathy (TTC) is a nonischemic cardiomyopathy in which there is a
“transient left ventricular systolic dysfunction,
sparing the basal segments of the left
ventricle” which results in an apical ballooning
appearance of the left ventricle (LV) (Lesser,
Maron & Sharkey, 2011).
-The name originates from the apical
ballooning shape, found via left
ventriculography or echocardiogram, that is
similar to a Japanese octopus trap called
“takotsubo” (Reeder & Prasad, 2015). Other
common names include apical ballooning
syndrome, stress-induced cardiomyopathy or
broken heart syndrome (Reeder & Prasad,
2015).

Proposed Underlying
Pathophysiology

Increased Catecholamine Levels
-The first includes increased levels of
circulating catecholamines that cause
decreased contractility and myocardial
stunning (Pelliccia, Greco, Vitale, Rosano,
Gaudio & Kaski, 2014). It is believed that
increased catecholamines damage myocytes
through cyclic adenosine monophosphate
(CAMP) calcium overload and increased levels
of free radiacls (Pelliccia, Greco, Vitale, Rosano,
Gaudio & Kaski, 2014).

Coronary Artery Vasospasm &
Microvascular Dysfunction.

-Another common hypothesis includes
coronary artery vasospasm and coronary artery
microvascular dysfunction producing the
transient left ventricular dysfunction found in
TTC (Liang, Cha, Oh, Prasad, 2013). Arterial
vasospasm of large epicardial coronary arteries
and microvascular coronary arteries are known
to have the potential to cause significant
cardiac disease as Prinzmetal’s angina

-Ultimately, regardless of the cause treatment must be provided to avoid
worsening of LV dysfunction, which can lead to ventricular arrhythmias,
permanent ventricular dysfunction and/or death. Since TTC initially presents in
a similar fashion as ACS, the treatment of the patient should follow ACS
guidelines initially until ACS can be ruled out and TTC made. Frequently this
involves coronary angiography, either emergently or urgently, to rule out
obstructive coronary artery disease (Scantlebury & Prasad, 2014).

Treatment
-Fortunately, conservative therapy that mimics general heart failure
treatment is successful at resolving most cases of TTC (Reeder & Prasad,
2015). Due to the lack of a unified, accepted theory for the underlying
pathophysiology of TTC a large amount of treatment is supportive in nature,
attempts to avoid the provocation of proposed causes and mirrors treatment
for heart failure. No evidence based treatment currently exists for TTC
(Reeder & Prasad, 2015).
-If profound shock is present treatment may include mechanical therapy,
such as insertion of an intra-aortic balloon pump (IABP), or inotropic therapy if
necessary.
-Ideally inotropes should be avoided given a surge in catecholamines is
theorized to be one of the causative factors of the disease (Reeder & Prasad,
2015).
-Initially beta blockers, angiotension-convering enzyme inhibitors (ACEIs) or
angiotensin receptor blockers (ARBs) and diuretics should be used to treat LV
dysfunction (Kono & Sabbah, 2014).
-Anticoagulation should be used in severe cases of LV failure to prevent
thromboembolism (Reeder & Prasad, 2015) which could cause stroke or other
end-organ ischemia.
-Beta blockers have been used in some patients after recovery of LV
function due to their catecholamine-inhibiting nature however there is no
conclusive standard of care on TTC treatment (Reeder & Prasad, 2015).
-ACEIs/ARBs, diuretics and anticoagulation should be discontinued after LV
recovery unless there are other concomitant diseases requiring their use
(Andrade & Stainback, 2014).

Pathophysiology
Signs & Symptoms

-TTC frequently mimics a ST-segment elevated myocardial infarction (STEMI) and/or acute coronary
syndrome (ACS) with acute chest pain, dyspnea, syncope and/or signs of heart failure (Reeder &
Prasad, 2015) with severe cases presenting in cardiogenic shock (Liang, Cha, Oh & Prasad, 2013).
Treatment for TTC is generally supportive, with the disease being predominantly benign in nature,
though some individuals presenting with severe symptoms experience high mortality rates (Liang,
Cha, Oh & Prasad, 2013).
-The onset of the disease is often caused by an intense emotional stressor such as the loss of a
loved one, an interpersonal conflict or a catastrophic medical diagnosis (Sharkey, Pink, Lesser,
Garberich, Maron & Maron, 2015) but can have physical triggers such as infection, surgery or
respiratory failure, while some have no obvious inciting events or diseases. Women, particularly postmenopausal women, are at a much greater risk than males for developing TTC with approximately
90% of cases occurring in females (Minhas, Hughey & Kolias, 2015).
-The similarity in symptoms is both a blessing and a curse as patients who experience the
aforementioned symptoms typically seek medical attention relatively quickly as they often associate
the symptoms with a heart attack. These same symptoms can easily be interpreted as ACS or a STEMI
by healthcare providers, as there is no unique sign or symptom to distinguish between the two
differential diagnoses, so individuals presenting with similar symptoms are often treated alike until
proven otherwise (Scantlebury & Prasad, 2014).

Implications for
Nursing Care
Monitoring

-In the acute care setting, care for
patients with TTC should include close
hemodynamic and electrocardiographic
monitoring as shock and malignant
arrhythmias are known to occur, and are
the biggest contributors of death from TTC
(Liang, Cha, Oh, Prasad, 2013).

Treatment

-Administration of appropriate
medications ACEIs/ARBs, diuretics, beta
blockers and possibly anticoagulation
should be provided to promote recovery of
LV function (Andrade & Stainback, 2014).

Trigger Identification &
Avoidance

-A thorough history and assessment
may provide clues to a possible emotional
or physical trigger, if one exists (Inggs &
Christensen, 2015).
-If a trigger is identified education
specific to avoiding that trigger may prove
beneficial, as 1 in 20 patients can suffer a
recurrence of the disease (Lesser, Maron &
Sharkey, 2011).

Education

-Medication and disease education
should be provided to improve compliance
with treatment to help increase the
chances of a full recovery (Lesser, Maron &
Sharkey, 2011).
-Education regarding anginal symptoms
(Pore & Burley, 2012) should be provided
as TTC patients could experience occlusive
coronary artery disease in the future and
they should not omit seeking treatment
because they have had or are recovering
from TTC.

Summary of Treatment
-Conservative therapy that mimics general heart failure treatment
-Profound shock treatment à IABP & inotropic therapy if necessary
-Avoidance of inotropes if possible due to their possible role in the disease
-Beta blockers, ACEIs or ARBs and diuretics for LV dysfunction
-Individualized discontinuation of treatment with recovery

Conclusions
-While TTC remains a relatively
benign condition with a good prognosis for
complete recovery, the three-fold increase
in recognized cases between 2007-2012
demands awareness of the condition
(Minhas, Hughey & Kolias, 2015).
-While most cases carry low
mortality rates, cardiogenic shock and
cardiac arrest can accompany TTC in
severe cases contributing to increased
mortality rates in certain cases (Liang, Cha,
Oh & Prasad, 2013).
-This varied presentation of the
disease can make the diagnosis of TTC
difficult, with a diagnosis typically made
after invasive cardiovascular testing is
complete (Reeder & Prasad, 2015).
-While both increased levels of
circulating catecholamines and coronary
artery vasospasm/dysfunction are strong
theories for the cause of TTC a definitive
cause is yet to be identified (Lesser, Maron
& Sharkey, 2011).
-Interestingly TTC is usually triggered
by a physical or emotional stressor in the
patient’s life and occurs predominantly in
females, though mortality rates in males
can be up to four times higher than
females (Khera, Light-McGroary, Kahr,
Horwitz & Girotra, 2016).
-Treatment primarily mirrors that of
congestive heart failure and can usually be
discontinued after return of LV function
(typically within weeks of condition onset)
with recurrence rates of the condition
around 5% (Lesser, Maron & Sharkey,
2011).

Mayo Clinic Criteria for Takotsubo Cardiomyopathy
1. Transient hypokinesis, akinesis, or dyskinesis of the left ventricular mid-segments with or without apical involvement;
the regional wall motion abnormalities extend beyond a single epicardial vascular distribution; a stressful trigger is
often, but not always present.

2. Absence of obstructive coronary disease or angiographic evidence of acute plaque rupture.

3. New electrocardiographic abnormalities (either ST-segment elevation and/or T-wave inversion) or modest elevation
in cardiac troponin.

4. Absence of pheochromocytoma and myocarditis

Figure 1 Pelliccia, Greco, Vitale, Rosano, Gaudio, & Kaski, 2014

Diagnostic Tests & Features
-Typical cardiac diagnostic tests for ACS, STEMI and TTC frequently share similar results, including
ST-segment changes on EKG, elevated cardiac biomarkers and wall motion abnormalities on
echocardiogram.
-Emergent or urgent coronary angiography is frequently required to exclude the diagnosis of ACS or
STEMI as delays in treatment for these diagnoses can lead to great increases in morbidity and
mortality (Hafiz, Naidu, DeLeon, Ismal, Alkhatib, Lorenz, E’Elia, Rosenthal & Marzo, 2013).
-A diagnostic feature of TTC found on coronary angiography and echocardiography is wall motion
abnormalities of the LV mid-segments with or without apical involvement that extend beyond a single
coronary artery distribution (Scantlebury & Prasad, 2014).
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